

Appendix A

Claim Amendments

1. (Currently amended) ~~Pharmaceutical~~ A pharmaceutical suspension formulation comprising
 - a. particles of formoterol or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, said particles being suspended in the formulation,
 - b. particles of ciclesonide or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, said particles being suspended in the formulation and
 - c. a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof.

2. (Currently amended) ~~Pharmaceutical~~ The pharmaceutical suspension formulation according to claim 1 ~~consisting~~ of comprising
 - a. particles of micronized formoterol, or a pharmaceutically acceptable salt, solvate or

physiologically functional derivative thereof, said particles being suspended in the formulation,

b. particles of micronized ciclesonide or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, said particles being suspended in the formulation,

c. ethanol,

d. a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof and

e. optionally a surfactant.

3. (Currently amended) ~~Suspension~~ The pharmaceutical suspension formulation according to claim 1 ~~any of the preceding claims~~ containing less than 3% by weight of ethanol.

4. (Currently amended) ~~Pharmaceutical~~ The pharmaceutical suspension formulation according to claim 1 ~~consisting of~~ comprising

a. particles of micronized formoterol, or a pharmaceutically acceptable salt, solvate or

physiologically functional derivative thereof, said particles being suspended in the formulation,

b. particles of micronized ciclesonide or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, said particles being suspended in the formulation,

c. a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof and

d. a surfactant.

5. (Currently amended) ~~Suspension~~ The pharmaceutical suspension formulation according to claim 1 which comprises ~~any of the proceeding claims containing~~ R,R-formoterol.

6. (Currently amended) ~~Suspension~~ The pharmaceutical suspension formulation according to claim 1 which comprises ~~any of the proceeding claims containing~~ formoterol fumarate dihydrate.

7. (Currently amended) ~~Suspension~~ The pharmaceutical suspension formulation according to claim 1 which

comprises ~~any of the proceeding claims containing~~ oleic acid as surfactant.

8. (Currently amended) ~~Suspension~~ The pharmaceutical suspension formulation according to claim 1 which comprises ~~any of the proceeding claims containing~~ about 0.001 to 0.1 % (w/w) of oleic acid.
9. (Currently amended) ~~Suspension~~ The pharmaceutical suspension formulation according to claim 1 which comprises ~~any of the proceeding claims containing~~ HFA 227 as propellant.
10. (Currently amended) ~~Suspension~~ The pharmaceutical suspension formulation according to claim 1 comprising ~~containing~~ disodium chromoglycate at a concentration which is ~~concentrations, which are~~ not therapeutically and/or prophylactically active.
11. (Currently amended) ~~Suspension~~ The pharmaceutical suspension formulation according to claim 1, which is administered in a once daily dosing regimen.